Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Advances in allogeneic CAR-T therapy in lymphoma

Yi Lin • 11 Jun 2022
EHA 2022
Lymphoma CAR-T

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses advances in allogeneic CAR-T therapy for the treatment of relapsed/refractory (R/R) lymphoma. Dr Lin first highlights the challenges surrounding the use of autologous CAR-T therapy, and then goes on to discuss the excitement surrounding the use of allogeneic products. To conclude, Dr Lin comments on the importance of further investigating the safety and efficacy of allogeneic CAR-Ts, and the promise of these agents for the future treatment of R/R disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Yi Lin

1:59
Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:50
Real-world outcomes of teclistamab treatment in R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:32
AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
Yi Lin • 9 Dec 2023
3:04
Outpatient monitoring following CAR-T and BsAb treatment for patients with lymphoma and MM
Yi Lin • 9 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals